Charlotte H. Ahern

2.6k total citations · 1 hit paper
42 papers, 2.0k citations indexed

About

Charlotte H. Ahern is a scholar working on Oncology, Neurology and Molecular Biology. According to data from OpenAlex, Charlotte H. Ahern has authored 42 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 19 papers in Neurology and 14 papers in Molecular Biology. Recurrent topics in Charlotte H. Ahern's work include Neuroblastoma Research and Treatments (18 papers), Pancreatic and Hepatic Oncology Research (11 papers) and Virus-based gene therapy research (4 papers). Charlotte H. Ahern is often cited by papers focused on Neuroblastoma Research and Treatments (18 papers), Pancreatic and Hepatic Oncology Research (11 papers) and Virus-based gene therapy research (4 papers). Charlotte H. Ahern collaborates with scholars based in United States, Canada and Switzerland. Charlotte H. Ahern's co-authors include Susan M. Blaney, Brenda J. Weigel, Ashish M. Ingle, Peter C. Adamson, Stephan D. Voss, Joel M. Reid, Yaël P. Mossé, John M. Maris, Frank M. Balis and Julie Laliberté and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Charlotte H. Ahern

42 papers receiving 1.9k citations

Hit Papers

Safety and activity of cr... 2013 2026 2017 2021 2013 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study
    2013 477 citations Yaël P. Mossé, Megan S. Lim et al. The Lancet Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Charlotte H. Ahern 798 756 571 541 338 42 2.0k
Hans-Jürgen Holzhausen 562 0.7× 612 0.8× 220 0.4× 532 1.0× 330 1.0× 71 2.0k
József Zsíros 443 0.6× 657 0.9× 380 0.7× 239 0.4× 250 0.7× 49 1.9k
Nicole Mentens 766 1.0× 449 0.6× 204 0.4× 619 1.1× 178 0.5× 33 2.4k
Nick Bown 1.3k 1.6× 663 0.9× 1.3k 2.3× 307 0.6× 593 1.8× 74 3.1k
Jonathan Keith Killian 725 0.9× 382 0.5× 169 0.3× 478 0.9× 432 1.3× 62 1.6k
Kuan‐Ting Kuo 1.1k 1.4× 643 0.9× 149 0.3× 353 0.7× 552 1.6× 85 2.7k
Fabio Bozzi 602 0.8× 526 0.7× 190 0.3× 662 1.2× 229 0.7× 49 1.9k
Peter Ho 1.1k 1.4× 780 1.0× 136 0.2× 354 0.7× 203 0.6× 48 2.0k
Irina A. Lubensky 1.1k 1.3× 635 0.8× 319 0.6× 815 1.5× 652 1.9× 41 2.2k
Mária Dudás 806 1.0× 650 0.9× 134 0.2× 822 1.5× 497 1.5× 22 2.0k

Countries citing papers authored by Charlotte H. Ahern

Since Specialization
Citations

This map shows the geographic impact of Charlotte H. Ahern's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charlotte H. Ahern with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charlotte H. Ahern more than expected).

Fields of papers citing papers by Charlotte H. Ahern

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charlotte H. Ahern. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charlotte H. Ahern. The network helps show where Charlotte H. Ahern may publish in the future.

Co-authorship network of co-authors of Charlotte H. Ahern

This figure shows the co-authorship network connecting the top 25 collaborators of Charlotte H. Ahern. A scholar is included among the top collaborators of Charlotte H. Ahern based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charlotte H. Ahern. Charlotte H. Ahern is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Greengard, Emily, Yaël P. Mossé, Xiaowei Liu, et al.. (2015). Safety and tolerability of crizotinib in combination with chemotherapy for relapsed or refractory solid tumors or anaplastic large cell lymphoma: a Children’s Oncology Group phase I consortium study.. Journal of Clinical Oncology. 33(15_suppl). 10058–10058. 5 indexed citations
2.
Loh, Mignon L., Sarah K. Tasian, Karen R. Rabin, et al.. (2015). A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011). Pediatric Blood & Cancer. 62(10). 1717–1724. 89 indexed citations
3.
Fouladi, Maryam, John P. Perentesis, Lars M. Wagner, et al.. (2014). A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report. Clinical Cancer Research. 21(7). 1558–1565. 16 indexed citations
4.
Ahern, Charlotte H., Ya‐Chen Tina Shih, Wenli Dong, Giovanni Parmigiani, & Yu Shen. (2014). Cost-effectiveness of alternative strategies for integrating MRI into breast cancer screening for women at high risk. British Journal of Cancer. 111(8). 1542–1551. 38 indexed citations
5.
Geller, James I., John P. Perentesis, Charlotte H. Ahern, et al.. (2014). A phase 1 study of the c-Met inhibitor tivantinib (ARQ 197, IND#112603) in children with relapsed or refractory solid tumors: A Children’s Oncology Group study.. Journal of Clinical Oncology. 32(15_suppl). 2627–2627. 1 indexed citations
6.
Tasian, Sarah K., Mignon L. Loh, Karen R. Rabin, et al.. (2014). A phase I study of ruxolitinib in children with relapsed/refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group Phase I Consortium study (ADVL1011).. Journal of Clinical Oncology. 32(15_suppl). 10019–10019. 1 indexed citations
7.
Bender, Julia Glade, Alice Lee, Joel M. Reid, et al.. (2013). Phase I Pharmacokinetic and Pharmacodynamic Study of Pazopanib in Children With Soft Tissue Sarcoma and Other Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report. Journal of Clinical Oncology. 31(24). 3034–3043. 125 indexed citations
8.
Mossé, Yaël P., Megan S. Lim, Stephan D. Voss, et al.. (2013). Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. The Lancet Oncology. 14(6). 472–480. 477 indexed citations breakdown →
9.
Bender, Julia Glade, Susan M. Blaney, Scott C. Borinstein, et al.. (2012). A Phase I Trial and Pharmacokinetic Study of Aflibercept (VEGF Trap) in Children with Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report. Clinical Cancer Research. 18(18). 5081–5089. 16 indexed citations
10.
Muscal, Jodi A., Patrick A. Thompson, Terzah M. Horton, et al.. (2012). A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: A Children's Oncology Group phase I consortium study (ADVL0916). Pediatric Blood & Cancer. 60(3). 390–395. 66 indexed citations
11.
Malempati, Suman, Brenda J. Weigel, Ashish M. Ingle, et al.. (2011). Phase I/II Trial and Pharmacokinetic Study of Cixutumumab in Pediatric Patients With Refractory Solid Tumors and Ewing Sarcoma: A Report From the Children's Oncology Group. Journal of Clinical Oncology. 30(3). 256–262. 147 indexed citations
12.
Fisher, William E., Sally E. Hodges, Eric J. Silberfein, et al.. (2011). Pancreatic resection without routine intraperitoneal drainage. HPB. 13(7). 503–510. 83 indexed citations
13.
DuBois, Steven G., Suzanne Shusterman, Joel M. Reid, et al.. (2011). Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children’s Oncology Group study. Cancer Chemotherapy and Pharmacology. 69(4). 1021–1027. 32 indexed citations
14.
Balentine, Courtney J., José M. Enríquez–Navascués, Sally E. Hodges, et al.. (2011). Obesity Does Not Increase Complications Following Pancreatic Surgery. Journal of Surgical Research. 170(2). 220–225. 26 indexed citations
15.
Ahern, Charlotte H., et al.. (2011). Risk-Specific Optimal Cancer Screening Schedules: An Application to Breast Cancer Early Detection. Statistics in Biosciences. 3(2). 169–186. 5 indexed citations
16.
Muscal, Jodi A., Philip A. Thompson, Charlotte H. Ahern, et al.. (2011). A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: A Children's Oncology Group study.. Journal of Clinical Oncology. 29(15_suppl). 9522–9522. 1 indexed citations
17.
Hummel, Trent R., Lars M. Wagner, Charlotte H. Ahern, et al.. (2011). A pediatric phase I trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: A Children’s Oncology Group Phase I Consortium Study.. Journal of Clinical Oncology. 29(15_suppl). 9579–9579. 4 indexed citations
18.
19.
Li, Min, Yu‐Qing Zhang, Uddalak Bharadwaj, et al.. (2009). Down-regulation of ZIP4 by RNA Interference Inhibits Pancreatic Cancer Growth and Increases the Survival of Nude Mice with Pancreatic Cancer Xenografts. Clinical Cancer Research. 15(19). 5993–6001. 86 indexed citations
20.
Malempati, Suman, Brenda J. Weigel, Charlotte H. Ahern, et al.. (2009). A phase I trial and pharmacokinetic study of IMC-A12 in pediatric patients with relapsed/refractory solid tumors: A Children's Oncology Group Phase I Consortium study. Journal of Clinical Oncology. 27(15_suppl). 10013–10013. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hans-Jürgen Holzhausen Breakdown of academic impact, for papers by József Zsíros Breakdown of academic impact, for papers by Nicole Mentens Breakdown of academic impact, for papers by Nick Bown Breakdown of academic impact, for papers by Jonathan Keith Killian Breakdown of academic impact, for papers by Kuan‐Ting Kuo Breakdown of academic impact, for papers by Fabio Bozzi Breakdown of academic impact, for papers by Peter Ho Breakdown of academic impact, for papers by Irina A. Lubensky Breakdown of academic impact, for papers by Mária Dudás
Rankless by CCL
2026